ArticleAmerican journal of cancer research2026
ITPKA promotes invasive phenotypes in clear cell renal cell carcinoma through functional modulation of PPAR signaling.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inositol-trisphosphate 3-kinase A (ITPKA) has been implicated in tumor progression; however, its potential role in clear cell renal cell carcinoma (ccRCC) remains insufficiently defined. This study investigated the expression pattern, prognostic relevance, and potential functional associations of ITPKA in ccRCC. Bioinformatic analyses were performed using TCGA and GEPIA2 datasets to evaluate ITPKA expression, clinicopathological relevance, survival associations, immune infiltration patterns, and enriched signaling pathways. Immunohistochemical (IHC) staining was conducted in 20 paired ccRCC and adjacent non-tumor tissue samples to provide exploratory protein-level validation. Functional assays were performed in 786-O cells following ITPKA knockdown or overexpression. Rescue assays targeting PPAR pathway, using the PPARγ antagonist GW9662 and PPARG overexpression, were used to examine whether PPAR signaling mediates ITPKA-associated cellular phenotypes. ITPKA expression was upregulated in ccRCC tissues and associated with adverse clinicopathological characteristics and unfavorable survival outcomes in the TCGA-KIRC cohort. Exploratory IHC analysis confirmed stronger ITPKA staining in ccRCC tissues than in matched adjacent normal tissues. Immune infiltration analysis suggested a possible association between ITPKA expression and specific immune cell populations, particularly Treg and Th2 cells. In 786-O cells, ITPKA knockdown attenuated malignant cellular phenotypes, including migration and invasion. Rescue assays showed that PPARγ inhibition with GW9662 partially reversed the effects of ITPKA knockdown, whereas PPARG overexpression attenuated the phenotypic changes induced by ITPKA overexpression. However, the present study does not establish a direct biochemical interaction between ITPKA and PPAR pathway components. In conclusion, ITPKA may serve as a potential biomarker and functional regulator in ccRCC. These findings provide preliminary evidence for an ITPKA-PPAR-related regulatory axis and warrant further validation in larger clinical cohorts and additional experimental models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.